Economic evaluation of other second generation agents is forthcoming. At this time, preliminary data comparing olanzapine with haloperidol treatment indicate greater cost savings with olanzapine primarily based on reduced hospitalization rates and durations. No data are available regarding the other second generation agents.
It is important to keep in mind that cost effectiveness from a societal perspective does not necessarily apply to the individual patient responsible for paying for his or her own treatment. A minority of patients with schizophrenia pay for their antipsychotic medication. For these patients, an agent should be chosen that is within the patient’s budget. buy diabetes drugs
The advent of the second generation antipsychotics has heralded the possibility of more effectively managing the complex symptoms of schizophrenia. However, the availability of these agents has also made selection of appropriate treatment difficult. The single major advance with these agents is their reduced propensity for EPS and TD. The purported advantage for negative symptoms compared with conventional agents has been inconsistent and may not be clinically meaningful for many patients. It is essential that clinicians be aware of the varied advantages and risks among the newer agents and compared with the conventional antipsychotics. This knowledge will become increasingly important as other second generation antipsychotics become accessible.